PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives
- Alternative title
-
PARP-Inhibitoren beim rezidivierenden Ovarialkarzinom, aktuelle Therapieoptionen und zukünftige Entwicklungen
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives ; volume:76 ; number:02 ; year:2016 ; pages:164-169
Geburtshilfe und Frauenheilkunde ; 76, Heft 02 (2016), 164-169
- Contributor
-
Sehouli, J.
Braicu, E. I.
Chekerov, R.
- DOI
-
10.1055/s-0035-1558185
- URN
-
urn:nbn:de:101:1-2019011114175943962243
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 14.08.2025, 8:46 AM UTC
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Sehouli, J.
- Braicu, E. I.
- Chekerov, R.
Other Objects (12)
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options
An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer
Combined inhibition of BADSer99 phosphorylation and PARP ablates models of recurrent ovarian carcinoma
PARP Inhibitors in Ovarian Cancer: A Review
Advances and perspectives of PARP inhibitors
PARP inhibitors in the treatment of ovarian cancer
New treatment option for ovarian cancer: PARP inhibitors
Impact of PARP inhibitors on progression-free survival in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective analysis
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Surgery in recurrent ovarian cancer
KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer
KLF5 Promotes Tumor Progression and Parp Inhibitor Resistance in Ovarian Cancer
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options
An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer
Combined inhibition of BADSer99 phosphorylation and PARP ablates models of recurrent ovarian carcinoma
PARP Inhibitors in Ovarian Cancer: A Review
Advances and perspectives of PARP inhibitors
PARP inhibitors in the treatment of ovarian cancer
New treatment option for ovarian cancer: PARP inhibitors
Impact of PARP inhibitors on progression-free survival in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective analysis
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Surgery in recurrent ovarian cancer
KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer
KLF5 Promotes Tumor Progression and Parp Inhibitor Resistance in Ovarian Cancer
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options
An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer
Combined inhibition of BADSer99 phosphorylation and PARP ablates models of recurrent ovarian carcinoma
PARP Inhibitors in Ovarian Cancer: A Review
Advances and perspectives of PARP inhibitors
PARP inhibitors in the treatment of ovarian cancer
New treatment option for ovarian cancer: PARP inhibitors
Impact of PARP inhibitors on progression-free survival in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective analysis
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Surgery in recurrent ovarian cancer
KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer